Heron Therapeutics, Inc.
HRTX
$0.41
$0.001.16%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -174.58% | 83.12% | -634.78% | -190.36% | -28.06% |
| Total Depreciation and Amortization | -1.49% | -12.68% | 0.65% | 10.89% | -5.16% |
| Total Amortization of Deferred Charges | 7.84% | 4.08% | -4.85% | -2.37% | -29.67% |
| Total Other Non-Cash Items | 35.51% | -85.43% | 434.98% | 22.36% | 8.77% |
| Change in Net Operating Assets | 132.90% | -349.07% | 130.36% | 17.09% | 21.15% |
| Cash from Operations | 83.23% | -790.01% | 112.25% | -22.53% | 24.70% |
| Capital Expenditure | -- | -- | 100.00% | -90.83% | 82.92% |
| Sale of Property, Plant, and Equipment | -- | -44.83% | 163.64% | -73.81% | 55.56% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 89.99% | -146.26% | 57.07% | 221.84% | -80.55% |
| Cash from Investing | 82.79% | -146.01% | 61.69% | 222.66% | -80.09% |
| Total Debt Issued | -- | -103.37% | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 3,732.70% | 717.19% | -84.87% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -100.00% | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.81% | 196.08% | -2,650.78% | -- | -- |
| Cash from Financing | -123.29% | -98.36% | 1,611.01% | 1,120.31% | -84.87% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 82.46% | -154.31% | 1,064.48% | 57.86% | -10,809.84% |